This is a review of the analysis of the RESONATE study with up to six years of follow-up on ibrutinib in patients with previously treated CLL or SLL.
Commentary is provided by Professor Stephen Opat an active member of the Monash Health Translation Precinct and Principal investigator in over 30 clinical trials mainly in lymphoid cancer. He is also the founder of the Australasian Lymphoma and Related Diseases Registry.
Please login below to download this issue (PDF)